Xiang Zhao

Dr. Xiang Zhao


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2024 in ACS Nano
Verified
Journal Article
Open access
ZPZaihui Peng
Zaihui Peng
TZTingting Zhao
Tingting Zhao
PGPingping Gao
Pingping Gao
GZGuozhi Zhang
Guozhi Zhang
XWXiujuan Wu
Xiujuan Wu
XQXiaowei Qi
Xiaowei Qi
Triple-negative breast cancer (TNBC) is highly heterogeneous, lacks accessible therapeutic targets, and features an immunosuppressive tumor microenvironment (TME). Anthracycline-based chemotherapy remains the primary treatment method for TNBC, while the current popular immune checkpoint inhibitors persistently encounter therapeutic resistance. Therefore, there is an urgent need to explore combined therapeutic strategies to remodel the TME and improve the treatment response. Considering the highly specific homing ability of tumor cell-derived vesicles and the key role of the signal transduction and activation of the transcription factor 3 (STAT3) pathway in TNBC, we propose a synergistic therapeutic strategy that integrates gene therapy, chemotherapy, and immunotherapy based on STAT3 short interfering RNA (siSTAT3) and doxorubicin (DOX)-functionalized tumor-derived extracellular vesicles (TEVs) (siSTAT3-DOX@TEV). The in vitro and in vivo results demonstrate that siSTAT3-DOX@TEV target tumor tissues precisely, downregulate STAT3 expression, and synergistically and efficiently induce immunogenic death, thereby reversing the immunosuppressive TME. Moreover, mass cytometry and immunohistochemistry reveal the local immune activation effect of siSTAT3-DOX@TEV, with a significant increase in M1 macrophages, CD4+ T cells, and CD8+ T cells in tumor tissues. These results provide strong hints for the development of TEV-based chemo-gene therapeutic agents for TNBC treatment at the clinical level.

9 January 2025 in Advanced Science
Verified
Journal Article
Open access
RZRuiyang Zi
Ruiyang Zi
XZXiang Zhao
Xiang Zhao
LLLimei Liu
Limei Liu
YWYijie Wang
Yijie Wang
RZRui Zhang
Rui Zhang
YDYan Dong
Yan Dong
Metabolic reprogramming of tumor cells dynamically reshapes the distribution of nutrients and signals in the tumor microenvironment (TME), affecting intercellular interactions and resulting in metabolic immune suppression. Increased glucose uptake and metabolism are characteristic of many tumors. Meanwhile, the progression of colorectal carcinoma (CRC) relies on lipid metabolism. Therefore, investigating the role of glucolipid metabolic reprogramming on tumor immunity contributes to identifying new targets for immune suppression intervention in CRC. Our previous work demonstrated that SIRT1 is the hub gene involved in glucolipid metabolic conversion in CRC. Here, it is found that upregulated SIRT1 in CRC cells increases Treg functionality by promoting the secretion of CX3CL1. The CX3CL1‐CX3CR1 signaling activated transcription factors SATB1 and BTG2, promoting the differentiation of TCF7 + Treg cells into functionally enhanced TNFRSF9 + Treg cells. Multiplex immunofluorescence (mIHC) analysis of a CRC tissue microarray confirmed the promoting effect of CX3CL1 on Treg infiltration. Additionally, the therapeutic efficacy of CX3CR1 inhibitor monotherapy and combination therapy is validated with the PD‐1 antibody in the humanized subcutaneous CRC mouse model. This study elucidates a potential mechanism that metabolic reprogramming of cancer cells collaborates with subsequent immunosuppression to promote CRC progression.

21 May 2025 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
GBGang Bai
Gang Bai
ZFZhichao Fan
Zhichao Fan
XZXiaoxin Zhao
Xiaoxin Zhao
YDYan Dong
Yan Dong
CTCongcong Tan
Congcong Tan
HYHua Yu
Hua Yu

12 March 2025 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
JZJie Zhou
Jie Zhou
XZXiaoqiuyan Zhang
Xiaoqiuyan Zhang
XXXingxing Xu
Xingxing Xu
YWYuanpei Wei
Yuanpei Wei
TZTianyu Zhang
Tianyu Zhang
MHMin Hu
Min Hu

31 March 2023 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
YQYuchen Qi
Yuchen Qi
XZXiang Zhao
Xiang Zhao
YDYan Dong
Yan Dong
MWMin Wang
Min Wang
JWJunyi Wang
Junyi Wang
JLJianjun Li
Jianjun Li
Extracellular vesicles (EVs) are increasingly recognized as important intermediaries of intercellular communication. They have significant roles in many physiological and pathological processes and show great promise as novel biomarkers of disease, therapeutic agents, and drug delivery tools. Existing studies have shown that natural killer cell-derived EVs (NEVs) can directly kill tumor cells and participate in the crosstalk of immune cells in the tumor microenvironment. NEVs own identical cytotoxic proteins, cytotoxic receptors, and cytokines as NK cells, which is the biological basis for their application in antitumor therapy. The nanoscale size and natural targeting property of NEVs enable precisely killing tumor cells. Moreover, endowing NEVs with a variety of fascinating capabilities via common engineering strategies has become a crucial direction for future research. Thus, here we provide a brief overview of the characteristics and physiological functions of the various types of NEVs, focusing on their production, isolation, functional characterization, and engineering strategies for their promising application as a cell-free modality for tumor immunotherapy.

5 February 2024 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
ZFZhichao Fan
Zhichao Fan
JZJie Zhou
Jie Zhou
QSQiuxia Shu
Qiuxia Shu
YDYan Dong
Yan Dong
YLYingxue Li
Yingxue Li
XZXiang Zhao
Xiang Zhao